This leaves little in the way of market incentives for manufacturers to develop vaccines, unless there are large numbers of people who are at risk in wealthy countries.
Zbog toga tržište nema inicijativu za proizvodnju i razvoj cjepiva osim ako velik broj ljudi koji riskiraju oboljenje nije u bogatim zemljama.